RDY:NYSE
Dr Reddy's Laboratories Ltd
USD 13,03
arrow_upward
+1,01%(+0,13) 1D
16 Okt., 15:49:44 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RDY...
Open
USD 13,00
High
USD 13,05
Low
USD 12,94
Mkt. cap
11,00 mjd
Avg. vol.
3,19 m
Volume
1,83 m
Dividend
0,64%
Quarterly dividend
USD 0,02
Ex-dividend date
10 Jul. 2026
P/E ratio
31,25
52-wk high
USD 15,67
52-wk low
USD 11,36
EPS
USD 0,42
Beta
0,30
Shares outstanding
834,64 m
No. of employees
28 k
Open
USD 13,00
High
USD 13,05
Low
USD 12,94
Mkt. cap
11,00 mjd
Avg. vol.
3,19 m
Volume
1,83 m
Dividend
0,64%
Quarterly dividend
USD 0,02
Ex-dividend date
10 Jul. 2026
P/E ratio
31,25
52-wk high
USD 15,67
52-wk low
USD 11,36
EPS
USD 0,42
Beta
0,30
Shares outstanding
834,64 m
No. of employees
28 k
News stories
From web sources and news partners
Livemint
·
1 uur gelede
Top 3 stocks to buy: Bajaj Finance, Dr Reddy's Lab, Grasim Industries by Sumeet Bagadia | Target price, stop-loss
CNBC TV18
·
9 uur gelede
Pharma Stocks: Macquarie sees margin pressure in Q2, upgrades Dr Reddy’s and Alkem
MarketBeat
·
14 uur gelede
Dr. Reddy's Laboratories (RDY) Expected to Announce Quarterly Earnings on Friday
ad-hoc-news.de
·
1 dag gelede
Dr Reddy reports three FDA observations: what it means for Dr Reddy stock
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 k
Founded1984
HeadquartersHyderabad, Andhra Pradesh, Indië
SectorPharmaceutical industry
Websitedrreddys.com